Novartis Investigative Site

Lleida 25198

3 studies enrolling now · 10 studies all time

What they study most

Carcinoma, Renal Cell, Generalized Myasthenia Gravis, IgA Nephropathy, Immunoglobulin A Nephropathy, Metastases, Brain, Neoplasms, Breast, Ovarian Cancer, Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS)

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Recruiting now
• A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis — Recruiting now
• A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. — Recruiting now
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Study of Zigakibart in Adults With IgA Nephropathy — Running, not enrolling
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Completed
• Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma — Completed
• Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer — Completed
• EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer — APPROVED_FOR_MARKETING